Bayer and Blackford Analysis have entered into a development and license agreement to establish an AI platform to integrate applications into the medical imaging workflow, designed to support complex decision-making and enhancing diagnostic confidence.
“Our agreement with Blackford Analysis reinforces our commitment to innovation in medical imaging. We want to drive AI-enabled radiology solutions that add clinical value by supporting radiologists and their teams in providing clear direction from diagnosis to care,” said Alexandre Salvador, head of digital business solutions for radiology at Bayer AG. “We are looking forward to combining our long-standing knowledge in life sciences and expertise in radiology with the technology and development capabilities of Blackford Analysis.”
The AI platform will provide access to a virtual marketplace through which healthcare professionals can obtain and manage various diagnostic imaging analysis applications, protocol management tools, departmental workflow tools and AI algorithms.
Blackford was spun-out from the University of Edinburgh in 2010 and offers instant comparison of multiple medical image studies with a single click.
“We are pleased to join forces with Bayer," said Ben Panter, Blackford Analysis CEO. "Easily integrated into existing workflows, our unique platform technology allows healthcare providers to use imaging information smartly.”
Under the terms of the agreement, Blackford Analysis will develop and provide platform technology for Bayer. Via the platform, Bayer will provide integrated AI solutions developed in-house and in cooperation with third parties, contributing with its medical and data science capabilities and deep disease understanding for various conditions.
